AbCellera Biologics Inc. (ABCL) P/E ratio

P/E ratio · fiscal 2022
20.3×

The P/E ratio of AbCellera Biologics Inc. (ABCL) was 20.3× at the end of fiscal 2022 (December 31, 2022). That is 32.0% lower than the 29.8× of fiscal 2021. Figures as of 18 Nov 2026, 04:25 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio, fiscal 2022
20.3×
Change on fiscal 2021
−32.0%
Highest on record
89.4×fiscal 2020
Lowest on record
20.3×fiscal 2022
Fiscal years on record
32020–2022

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

AbCellera Biologics Inc. P/E ratio, in more detail

Across the 3 fiscal year-ends on record (2020–2022), the highest was 89.4× in fiscal 2020 and the lowest 20.3× in fiscal 2022.

History · 3 fiscal years

P/E ratio at each fiscal year-end

AbCellera Biologics Inc. P/E ratio, year by year

AbCellera Biologics Inc. (ABCL) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
2025——$3.42-$0.49
2024——$2.93-$0.55
2023——$5.71-$0.51
202220.3× 32.0% down$10.13$0.50
202129.8× 66.7% down$14.30$0.48
202089.4×—$40.24$0.45
2019———-$0.01

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

More on ABCL

AbCellera Biologics Inc., figure by figure

AbCellera Biologics Inc. (ABCL) overview: price, valuation and scorecard

AbCellera Biologics Inc. P/E ratio: questions and answers

What is AbCellera Biologics Inc.'s P/E ratio?

The P/E ratio of AbCellera Biologics Inc. (ABCL) was 20.3× at the end of fiscal 2022 (December 31, 2022). That is 32.0% lower than the 29.8× of fiscal 2021.

What are the highest and lowest P/E ratio figures on record for AbCellera Biologics Inc.?

Across the 3 fiscal year-ends on record (2020–2022), the highest was 89.4× in fiscal 2020 and the lowest 20.3× in fiscal 2022.

How is AbCellera Biologics Inc.'s P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AbCellera Biologics Inc. (ABCL) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ABCL/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.